Numinus Wellness Inc.
NUMIF · OTC
Company research
Numinus Wellness Inc. (OTCQB: NUMIF; TSX: NUMI) is a Vancouver, Canada-based mental health care company dedicated to the development and delivery of innovative behavioral health treatments, with a core focus on safe, evidence-based psychedelic-assisted therapies. The company operates through key business segments including Numinus Health, a network of mental health clinics across Canada and the United States offering services such as ketamine-assisted therapies, traditional psychotherapy, counseling, neurofeedback, and transcranial magnetic stimulation, and Cedar Clinical Research, which provides clinical research management services to academic institutions and biotechnology companies. Numinus also supports the advancement of psychedelic medicine through laboratory services encompassing the cultivation, production, and analytical testing of psychedelic compounds such as psilocybin, as well as proprietary research and development activities. Led by CEO Michael Tan, the company pursues a vertically integrated model — spanning preclinical research, clinical operations, and practitioner training — aimed at transforming mental health care for conditions including depression, anxiety, trauma, and substance use disorders.
Research reports
Macroaxis provides a structured quantitative review of Numinus Wellness’ fundamentals, covering profitability, liquidity, leverage and efficiency and noting deeply negative return on equity and assets, modest revenue, and significant operating margin pressure while mapping these metrics to a target price of 0.50 USD and peer valuation multiples. The commentary characterizes the company’s financial organization as constructive but emphasizes that current earnings capacity is under strain, leaving the long‑term value realization dependent on improvements in cash flow quality and capital sustainability.
AInvest (AInvest Fintech Inc.) · August 8, 2025Numinus Wellness: A High-Growth Psychedelic-Therapy Play with Strong Operational Turnaround SignalsThis AInvest article presents Numinus as a high‑growth psychedelic‑therapy play, highlighting a 68.3% year‑over‑year revenue surge, roughly 49–51% gross margin, and a 51.1% cut in operating expenses in Q1 2025, driven by clinic divestitures, staff rationalization, and a shift to an asset‑light, AI‑enabled model. It argues that strategic moves such as selling Utah clinics, integrating MedBright AI, building a decentralized Numinus Network practitioner platform, and positioning for reimbursement in a forecasted 15.6% CAGR psychedelic‑therapy market support a high‑conviction long‑term investment case, while acknowledging regulatory timing, competitive entry, and stigma around psychedelics as key risks.